Is it time for NICE to revise its threshold?

By Mary Gabb ([email protected]) “There just isn’t, and never will be, enough money to provide every possible service” – a reminder to participants of the NICE Citizens Council (November 27–29, 2008) as they were asked to consider in what circumstances should NICE recommend interventions where the cost per QALY (quality-adjusted life-year) is above the threshold…

Canada healthcare – from paper to pixels

By Ruth Whittington ([email protected]) Many of us in health economics and outcomes research look at Canada as one of the leaders in the field; along with Australia , Canada was one of the first countries to demand evidence of cost-effectiveness as a prerequisite for drug approval. To those of us not intimately acquainted with its…

Alcohol and global warming – what’s the common theme?

By Ruth Whittington ([email protected]) According to Michael Wilks, Chairman of the Standing Committee of European Doctors (CPME; an organisation facing the challenges of its current 2 million doctors in 27 countries being expanded by an ever-growing EU), these are two major influences of healthcare provision. The CPME has subcommittees that deal with four areas concerning…

Making adherence work for your dollar (or pound, or euro…)

By Mary Gabb ([email protected]) As we reported in last month’s HOC, the past few years have witnessed a surge of interest in the role of adherence in health economics research, highlighted by a recent report from the National Council on Patient Information and Education (NCPIE) in the United States, which revealed the high rates of…